echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > A number of Class 1 new drugs were approved for clinical treatment of baldness, atopic dermatitis, etc.

    A number of Class 1 new drugs were approved for clinical treatment of baldness, atopic dermatitis, etc.

    • Last Update: 2021-11-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On September 27, the CDE official website showed that a number of Class 1 new drug clinical trial applications were approved by the China Food and Drug Administration.


    SHR-1819 injection targets IL-4R, which can block the interleukin pathway, inhibit the transmission of downstream inflammatory signals, and ultimately improve the inflammatory state of the disease and control the progression of the disease


    MIL62 is a new generation of type II CD20 antibody, which is optimized by Tianguangshi's independent innovation of glycosylated antibody technology platform


    Finasteride spray and LPM3770164 sustained-release tablets were both approved for clinical use for the first time


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.